We previously reported a benefit for all-trans retinoic acid (ATRA) in both induction and
maintenance therapy in patients with acute promyelocytic leukemia (APL). To determine the …

Background All-trans-retinoic acid induces complete remission in acute promyelocytic
leukemia. However, it is not clear whether induction therapy with all-trans-retinoic acid is …

All-trans-retinoic acid (ATRA) increases the efficacy of chemotherapy when used for
induction and maintenance treatment of acute promyelocytic leukemia (APL), but its role in …

All transretinoic acid (ATRA) followed by daunorubicin (DNR)-AraC chemotherapy (CT) has
improved the outcome of acute promyelocytic leukemia (APL) by comparison to CT alone. In …

First results of a randomized trial (APL91 trial) and other randomized or non-randomized
studies have shown that ATRA followed by chemotherapy significantly increased event-free …

All-trans retinoic acid (ATRA) can induce complete remission (CR) in most patients with
acute promyelocytic leukemia (APL) through in vivo differentiation of APL blasts. However, it …

It has been shown that all-trans retinoic acid (ATRA) at doses of 45 to 100 mg/m2/d induces
complete remission (CR) of acute promyelocytic leukemia (APL) by a differentiation process …

All-trans retinoic acid (ATRA) is an essential component of the treatment of acute
promyelocytic leukemia (APL), but the optimal timing and duration remain to be determined …

We entered 26 patients with newly diagnosed acute promyelocytic leukemia (APL) in a pilot
study of all-transretinoic acid (ATRA) followed by intensive chemotherapy. Median age was …

We conducted a multicenter trial of treatment with all-trans retinoic acid (ATRA) for newly
diagnosed acute promyelocytic leukemia (APL) in the AML-92 study and compared it with …